Informações de Absci Corp

Mais detalhes de Absci Corp Empresa

Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.



Código da empresaABSI

Nome da EmpresaAbsci Corp

Data de listagemJul 22, 2021

CEOMr. Sean Mcclain

Número de funcionários156

Tipo de títulosOrdinary Share

Fim do ano fiscalJul 22

Endereço18105 Se Mill Plain Blvd

CidadeVANCOUVER

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal98683

Telefone13609491041

Sitehttps://www.absci.com/

Código da empresaABSI

Data de listagemJul 22, 2021

CEOMr. Sean Mcclain

Executivos da empresa Absci Corp



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Sean Mcclain

Chief Executive Officer, Founder, Director

8.70M

-0.27%

Mr. Andreas Busch, Ph.D.

Chief Innovation Officer

128.39K

-2.35%

Dr. Zachariah (Zach) Jonasson, Ph.D.

Chief Financial Officer, Chief Business Officer

124.91K

-0.31%

Ms. Shelby J. Walker, J.D.

Chief Legal Officer

59.30K

--

Ms. Karen K. Mcginnis, CPA

Independent Director

29.50K

+96.67%

Mr. Daniel A. (Dan) Rabinovitsj

Independent Director

14.50K

--

Ms. Mary T. Szela

Director

--

Mr. Frans Van Houten

Independent Chairman of the Board

--

-100.00%

Prof. Dr. Menelas (Mene) Pangalos, Ph.D.

Independent Director

--

Dr. Joseph Sirosh, Ph.D.

Independent Director

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Sean Mcclain

Chief Executive Officer, Founder, Director

8.70M

-0.27%

Mr. Andreas Busch, Ph.D.

Chief Innovation Officer

128.39K

-2.35%

Dr. Zachariah (Zach) Jonasson, Ph.D.

Chief Financial Officer, Chief Business Officer

124.91K

-0.31%

Ms. Shelby J. Walker, J.D.

Chief Legal Officer

59.30K

--

Ms. Karen K. Mcginnis, CPA

Independent Director

29.50K

+96.67%

Mr. Daniel A. (Dan) Rabinovitsj

Independent Director

14.50K

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Fidelity Management & Research Company LLC

12.80%

ARK Investment Management LLC

6.72%

McClain (Sean)

5.82%

Redmile Group, LLC

5.52%

BlackRock Institutional Trust Company, N.A.

4.98%

Outro

64.16%

Investidores

Proporção

Fidelity Management & Research Company LLC

12.80%

ARK Investment Management LLC

6.72%

McClain (Sean)

5.82%

Redmile Group, LLC

5.52%

BlackRock Institutional Trust Company, N.A.

4.98%

Outro

64.16%

Tipos de investidores

Investidores

Proporção

Investment Advisor

35.64%

Investment Advisor/Hedge Fund

18.75%

Individual Investor

6.26%

Hedge Fund

3.58%

Corporation

3.17%

Research Firm

2.18%

Bank and Trust

0.28%

Venture Capital

0.16%

Insurance Company

0.03%

Outro

29.95%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

297

90.86M

60.76%

-3.89M

2025Q2

309

100.84M

69.96%

-2.94M

2025Q1

316

100.15M

78.58%

-546.74K

2024Q4

298

92.04M

80.13%

-8.74M

2024Q3

280

90.06M

79.27%

-8.98M

2024Q2

257

91.26M

83.61%

+4.72M

2024Q1

236

84.09M

77.41%

+14.50M

2023Q4

202

58.01M

62.41%

-6.63M

2023Q3

196

57.87M

62.40%

-7.67M

2023Q2

191

58.28M

63.02%

-12.48M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Fidelity Management & Research Company LLC

19.13M

12.8%

+747.00K

+4.06%

Jun 30, 2025

ARK Investment Management LLC

10.05M

6.72%

-909.16K

-8.30%

Jun 30, 2025

McClain (Sean)

8.73M

5.84%

+119.00K

+1.38%

Mar 31, 2025

Redmile Group, LLC

8.25M

5.52%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

7.45M

4.98%

+1.20M

+19.14%

Jun 30, 2025

The Vanguard Group, Inc.

6.45M

4.31%

+1.76M

+37.63%

Jun 30, 2025

Phoenix Ventures Partners II LP.

4.75M

3.17%

-4.61M

-49.28%

Mar 31, 2025

Fred Alger Management, LLC

3.93M

2.63%

-364.72K

-8.49%

Jun 30, 2025

Woodline Partners LP

2.97M

1.98%

+1.57M

+113.20%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.45M

1.64%

+448.98K

+22.49%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

ARK Genomic Revolution ETF

3.03%

WisdomTree BioRevolution Fund

1%

iShares Micro-Cap ETF

0.08%

ProShares Ultra Nasdaq Biotechnology

0.05%

Invesco Nasdaq Biotechnology ETF

0.04%

iShares Biotechnology ETF

0.04%

iShares Russell 2000 Growth ETF

0.02%

Avantis US Small Cap Equity ETF

0.02%

Proshares Ultra Russell 2000

0.01%

ProShares Hedge Replication ETF

0.01%

Ver Mais

ARK Genomic Revolution ETF

Proporção3.03%

WisdomTree BioRevolution Fund

Proporção1%

iShares Micro-Cap ETF

Proporção0.08%

ProShares Ultra Nasdaq Biotechnology

Proporção0.05%

Invesco Nasdaq Biotechnology ETF

Proporção0.04%

iShares Biotechnology ETF

Proporção0.04%

iShares Russell 2000 Growth ETF

Proporção0.02%

Avantis US Small Cap Equity ETF

Proporção0.02%

Proshares Ultra Russell 2000

Proporção0.01%

ProShares Hedge Replication ETF

Proporção0.01%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados